By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Despite short-term headwinds from Medicaid enrollment declines and flat Medicare reimbursements, the panel is divided on Elevance Health's (ELV) long-term prospects, with some seeing potential in the Carelon vertical integration play, while others remain skeptical due to regulatory risks and margin compression.
Risk: Structural margin compression due to declining Medicaid enrollment and flat Medicare reimbursement rates.
Opportunity: Potential offset of core insurance margin compression through Carelon's pharmacy benefit and care delivery ecosystem.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Hotchkis & Wiley, an investment management company, released its first-quarter 2026 investor letter for the “Hotchkis & Wiley Large Cap Fundamental Value Fund.” A copy of the letter can be downloaded here. In Q1 2026, the S&P 500 Index declined by -4.4%, driven by geopolitical uncertainty and AI investment themes. Brent crude oil surged over 100% due to U.S.-Israel strikes on Iran, benefiting the energy sector, which outperformed significantly. Value stocks surpassed growth, with the Russell 1000 Value Index gaining +2.1% compared to -9.8% for the Growth Index. However, the Hotchkis & Wiley Large Cap Fundamental Value Fund lagged, returning 0.36% vs. 2.10% for the Russell 1000 Value Index, driven by its overweight exposure in software and health insurers. However, the energy holdings, which returned +49%, were the portfolio's top performers. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Hotchkis & Wiley Large Cap Fundamental Value Fund highlighted stocks such as Elevance Health, Inc. (NYSE:ELV). Elevance Health, Inc. (NYSE:ELV) is a health benefits company that detracted from the Strategy’s performance in the quarter. On April 27, 2026, Elevance Health, Inc. (NYSE:ELV) closed at $356.13 per share. One-month return of Elevance Health, Inc. (NYSE:ELV) was 21.65%, and its shares lost 13.91% over the past 52 weeks. Elevance Health, Inc. (NYSE:ELV) has a market capitalization of $77.34 billion.
Hotchkis & Wiley Large Cap Fundamental Value Fund stated the following regarding Elevance Health, Inc. (NYSE:ELV) in its Q1 2026 investor letter:
"Elevance Health, Inc.(NYSE:ELV) is one of the largest health insurers, yet it trades at a discount to the broader market despite being a high quality business that grows faster than GDP and returns a significant portion of its cash to shareholders. Q1 performance was weak, driven by disappointing FY26 guidance amid declining Medicaid enrollment and flat Medicare reimbursement rates proposed by the Trump administration. We view these pressures as medium-term noise and believe Elevance has the ability to improve margins over time through benefit adjustments and/or higher premiums."
Elevance Health, Inc. (NYSE:ELV) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 78 hedge fund portfolios held Elevance Health, Inc. (NYSE:ELV) at the end of the fourth quarter, compared to 82 in the previous quarter. While we acknowledge the potential of Elevance Health, Inc. (NYSE:ELV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Four leading AI models discuss this article
"The combination of Medicaid attrition and capped Medicare reimbursement creates a structural margin ceiling that premium increases are unlikely to fully offset."
Elevance Health (ELV) is currently trapped in a structural squeeze. The market is pricing in a permanent margin compression due to the confluence of declining Medicaid enrollment—a high-margin revenue stream—and stagnant Medicare reimbursement rates. While Hotchkis & Wiley views these as 'medium-term noise,' they are actually fundamental shifts in the regulatory and demographic landscape. With the stock trading at a discount, the risk is not just valuation, but a potential reduction in long-term earnings power. Investors should monitor the medical loss ratio (MLR) closely; if it sustains above 88%, the 'margin improvement' thesis is effectively dead. I am skeptical that premium hikes alone can offset these systemic headwinds in a tightening political environment.
If ELV successfully pivots its product mix toward higher-margin commercial segments and leverages scale to force cost efficiencies, the current double-digit discount to the S&P 500 represents a generational entry point for a defensive cash-flow compounder.
"Hotchkis dismisses Medicaid declines and flat Medicare rates as 'medium-term noise,' but these signal multi-year policy risks under Trump that could structurally compress health insurer margins."
Hotchkis & Wiley frames Elevance Health (ELV) as undervalued long-term despite Q1 2026 weakness from FY26 guidance disappointment—declining Medicaid enrollment and Trump-proposed flat Medicare rates—betting on margin gains via benefit tweaks and premium hikes in a GDP-beating cash generator trading below market averages. Fund lagged Russell 1000 Value (+2.1%) due to overweight health insurers, while energy holdings surged +49% on oil spike. ELV up 21.7% in past month ($356 close, $77B cap) but down 13.9% over 52 weeks; hedge funds trimmed to 78 holders. Stress test: Medicaid declines are structural post-COVID redeterminations, not noise, and Trump policies risk entrenching reimbursement caps, eroding pricing power versus peers.
Hotchkis' deep value expertise and ELV's history of navigating cycles via scale-driven adjustments support their view that pressures are transitory, enabling margin expansion and multiple re-rating as enrollment stabilizes.
"ELV's valuation discount reflects real structural headwinds in 60%+ of revenue (Medicaid + Medicare), not temporary market mispricing, and the fund's margin-recovery thesis depends on pricing power that may not materialize in a cost-control-focused political environment."
ELV's valuation discount to market despite superior GDP+ growth and shareholder returns is genuinely unusual—but the article conflates two separate problems. Q1 guidance miss + Medicaid headwinds + flat Medicare reimbursement aren't 'medium-term noise'—they're structural margin compression in a 60%+ of revenue base. The fund's margin-improvement thesis hinges on pricing power (premium increases) or utilization cuts (benefit tightening), both politically fraught in a Trump administration focused on healthcare affordability. The 21.65% one-month bounce suggests oversold positioning, not fundamental repair. Watch whether Q2 enrollment stabilizes and whether CMS signals any Medicare rate flexibility—without both, the 'discount to market' may be justified.
If Medicaid disenrollment slows faster than expected and the Trump admin reverses course on Medicare rates (or allows private plan rate flexibility), ELV's operating leverage could surprise to the upside, justifying the fund's conviction despite near-term pain.
"Near-term earnings risk from Medicaid enrollment declines and Medicare reimbursement pressure could erase the expected margin thesis, even if long‑term upside remains intact."
The article frames Elevance Health (ELV) as a high‑quality insurer with a long‑term margin expansion path, citing Q1 weakness and policy headwinds as 'noise.' ELV trades around $356.13 (4/27/2026) with a one‑month gain of 21.65% but a 52‑week decline of 13.91%, signaling that near‑term catalysts are priced in. The risk is that Medicaid enrollment declines and flat Medicare reimbursements could persist, forcing premium or benefit adjustments that cap earnings upside. The article also relies on hedge‑fund churn data and a plug for AI plays, which may obscure real regulatory and medical‑cost risk. The upside hinges on margins expanding despite policy headwinds.
ELV could surprise to the upside if premium growth and cost discipline offset enrollment headwinds, and the market may be underpricing such optionality. If policy risk fades more quickly than expected, the investment thesis could re-rate.
"Elevance's vertical integration through Carelon provides a structural hedge against insurance margin compression that the current debate overlooks."
Claude and Gemini are fixated on the political headwinds, but you are all ignoring the 'Carelon' vertical integration play. Elevance isn't just an insurer; they are aggressively building a pharmacy benefit and care delivery ecosystem. If Carelon captures enough margin leakage from their own health plans, the MLR sensitivity decreases significantly. The market isn't just pricing in Medicaid risk; it's waiting to see if Carelon can actually scale enough to offset the core insurance margin compression.
"Carelon is currently increasing costs without proven MLR relief, exacerbating pressures from enrollment declines and policy risks."
Gemini, Carelon's vertical integration is margin-dilutive today—Q1 SG&A rose to 12.8% (vs. peers' ~10%) from ramp-up costs, with MLR climbing to 87.2% despite benefit tweaks. It won't offset Medicaid enrollment drops (down 500k+ YTD) or Medicare flat rates anytime soon; regulatory antitrust scrutiny on insurer PBMs adds tail risk. Investors betting on it are speculating on unproven scale in a hostile policy environment.
"Carelon's margin accretion timeline matters more than current SG&A drag; if captive PBM reaches $50B+ volume, core insurance margin compression becomes less determinative of ELV's long-term earnings power."
Grok's SG&A math is correct but incomplete. Carelon's 12.8% SG&A reflects startup drag, not structural inefficiency. The real question: does Carelon's PBM margin (typically 3-5% of spend) eventually exceed the SG&A overhead? If ELV captures $50B+ in captive pharmacy volume at 4% margin, that's $2B EBITDA offsetting core insurance compression. Grok conflates current dilution with permanent value destruction. Antitrust risk is real, but scale economics aren't speculative—they're standard PBM playbook.
"Carelon can help, but it's not a guaranteed near-term offset to ELV's structural margin compression; timing, integration risk, and regulatory headwinds imply a conditional payoff rather than a sure offset."
Claude’s Carelon payoff relies on PBM margins scaling to offset core MLR pressure, but that's a timing and execution risk with regulatory tailwinds. SG&A drag is not going away overnight, and even a $2B EBITDA lift assumes flawless integration and no antitrust constraint. If Carelon delivers later than the Medicaid headwinds resolve, ELV still faces structural margin compression. In short, Carelon helps, but it’s unlikely to unlock a guaranteed offset in the near term.
Despite short-term headwinds from Medicaid enrollment declines and flat Medicare reimbursements, the panel is divided on Elevance Health's (ELV) long-term prospects, with some seeing potential in the Carelon vertical integration play, while others remain skeptical due to regulatory risks and margin compression.
Potential offset of core insurance margin compression through Carelon's pharmacy benefit and care delivery ecosystem.
Structural margin compression due to declining Medicaid enrollment and flat Medicare reimbursement rates.